Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Thymoglobulin Induction Therapy in Kidney Transplantation (6mg/kg vs 4mg/kg)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02447822
Recruitment Status : Unknown
Verified May 2015 by Duck Jong Han, Asan Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : May 19, 2015
Last Update Posted : May 19, 2015
Sponsor:
Information provided by (Responsible Party):
Duck Jong Han, Asan Medical Center

Brief Summary:
This is a prospective randomized controlled study to evaluate feasibility and safety of early steroid withdrawal after 6mg/kg vs 4.5mg/kg Thymoglobulin induction therapy in kidney transplantation. Patients are enrolled from June, 2015 for 24 months. They are randomized to either 6mg/kg or 4.5mg/kg Thymoglobulin induction group. Steroid withdrawal is done within one week after kidney transplantation for all the patients. Maintenance immunosuppressants are Tacrolimus and Mycophenolate mofetil (or Myfortic). Primary outcome is a composite of biopsy-proven acute rejection, delayed graft function, graft loss or death within one year post transplant.

Condition or disease Intervention/treatment Phase
Kidney Failure Drug: Thymoglobulin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 154 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Randomized Controlled Study to Evaluate Feasibility and Safety of Early Steroid Withdrawal After 6mg/kg vs 4.5mg/kg Thymoglobulin Induction Therapy in Kidney Transplantation
Study Start Date : June 2015
Estimated Primary Completion Date : May 2018
Estimated Study Completion Date : May 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: 6.0ATG
Recipients who have 6.0 mg/kg Thymoglobulin as induction therapy
Drug: Thymoglobulin
6.0 mg/kg vs 4.5 mg/kg Thymoglobulin

Active Comparator: 4.5ATG
Recipients who have 4.5 mg/kg Thymoglobulin as induction therapy
Drug: Thymoglobulin
6.0 mg/kg vs 4.5 mg/kg Thymoglobulin




Primary Outcome Measures :
  1. A composite outcome of biopsy-proven acute rejection, delayed graft function, graft loss, and death [ Time Frame: 12 months after kidney transplantation ]

Secondary Outcome Measures :
  1. Pathologic findings according to Banff 2013 criteria [ Time Frame: 1 day at the time of biopsy ]
  2. Overall rate of acute rejection [ Time Frame: 12 months after kidney transplantation ]
  3. The rate of steroid-free immunosuppressive regimen [ Time Frame: 12 months after kidney transplantation ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female patients with renal failure from 18 to 70 years of age
  • Candidates for cadaveric or living donor kidney transplantation
  • Patients who are able and willing to consent the protocol of the study

Exclusion Criteria:

  • Patients who have been receiving immunosuppressive therapy before transplantation
  • Patients who have received an investigational medication within the past 30 days
  • Patients who have a known contraindication to the administration of antithymocyte globulin
  • Patients who are suspected or known to have an infection or were seropositive for hepatitis B surface antigen (HBsAg), antibody against hepatitis B core antigen (anti-HBcAg), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)
  • Patients who have had cancer (except non melanoma skin cancer) within the previous 2 years
  • Pregnant women, nursing mothers, and women of childbearing potential who were not using condoms or oral contraceptives
Layout table for additonal information
Responsible Party: Duck Jong Han, Professor, Asan Medical Center
ClinicalTrials.gov Identifier: NCT02447822    
Other Study ID Numbers: AsanMC 2014-1213
First Posted: May 19, 2015    Key Record Dates
Last Update Posted: May 19, 2015
Last Verified: May 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Thymoglobulin
Immunologic Factors
Physiological Effects of Drugs
Immunosuppressive Agents